MAPT and Alzheimer disease: Tau PET imaging, particularly with second-generation tracers that exhibit less off-target binding [4], may represent an informative biomarker for tau pathology in AD, as evidenced by its inclusion in the National Institute on Aging-Alzheimer’s Association (NIA-AA) Research Framework for biological diagnosis of AD [7] and FDA approval of [18F]flortaucipir for assessing NFT burden in suspected AD-associated cognitive impairment [8].